Key Drivers
- Liquidity Buffer
- Heavy Losses
- Weak Profitability
AIAI Summary
CLDX has meaningfully de-risked financing and execution with early Phase 3 enrollment and a $345M raise, but it is now a largely binary barzolvolimab bet with negligible revenue and heavy burn, so upside depends almost entirely on strong Q4 2026 data while any miss could reset the stock sharply lower.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Buffer
- •Heavy Losses
- •Weak Profitability
CLDX has strong liquidity and minimal debt, but its near-zero revenue, persistent large losses, and ongoing cash burn make profitability the main concern.
Price Behavior
Key Price Behavior Insights:
- •Failed bounce
- •Lower highs
- •Support test
CLDX remains in a short-term downtrend, with support at $31.2-$31.4 holding for now, but rallies keep failing below $32.5 and a break under $31.2 would weaken the setup further.
Rebounded to $34.39 on 2026-05-06, then quickly reversed back into the low $32s
Sentiment & News
Key News Insights:
- •Analyst Upside
- •Q1 Loss Miss
- •Phase 3 Progress
CLDX drew analyst optimism and strong barzolvolimab progress, but a wider-than-expected Q1 loss and revenue miss keep the stock focused on execution and upcoming clinical catalysts.
The news is likely to keep CLDX driven by upcoming trial data and financing strength, while near-term sentiment remains tempered by ongoing operating losses
Similar Companies in Healthcare
Other companies in the same sector with AI ratings